Dose Individualization of Pemetrexed - IMPROVE-II

Non Small Cell Lung Cancer Clinical Trial

— IMPROVE-II  

Official title:

Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03655821
• Other study ID #: IMPROVE-II
• Status: Terminated
• Phase: Phase 4
• Start date: February 1, 2019
• Est. completion date: May 11, 2021

Study information

• Verified date: May 2022
• Source: Radboud University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is currently not advised. Pemetrexed is dosed based on body surface area (BSA), while renal function and dose are the sole determinants for systemic exposure. This causes 3 major issues: 1. In patients with renal dysfunction, BSA-based dosing may lead to haematological toxicity 2. Patients have to discontinue treatment due to declining renal function, and are withheld effective treatment 3. Even in patients with adequate renal function (GFR >45 ml/min) treatment may be improved by individualized dosing based on renal function, resulting in less toxicity. Also, BSA-based dosing may lead to ineffective therapy in patients with above average renal function. The investigators aim to address these problems. Objective: The overall main objective is to develop a safe and effective individualized dosing regimen for pemetrexed. Study design: IMPROVE-II is an open label, double arm, randomized study to compare renal function-based dosing of pemetrexed versus BSA-based dosing on attainment of therapeutic exposure. Study population: IMPROVE-II includes 94 patients with NSCLC or mesothelioma that are eligible for pemetrexed treatment. Intervention: patients will be randomized in a 1:1 ratio to Arm A (BSA-based dosing according drug label) or to Arm B (renal function based dosing). The renal function-based dose will be calculated to reach the target AUC. Pharmacokinetic assessment after administration will be performed after the first pemetrexed dose in both arms. Main study endpoints: The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The investigators consider the extra burden from participating in the planned studies limited. The extra interventions compared to routine care, consist of sampling extra blood. The pharmacokinetic assessments require placement of one additional intravenous catheter. To ensure minimal impact of study participation on daily life, a limited sampling strategy will be used. Patients may benefit from participating in IMPROVE I and -II, as they will be treated with a potentially safe and effective drug that is dosed individually, which prevents toxic exposure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 81
• Est. completion date: May 11, 2021
• Est. primary completion date: May 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. =18 years old

2. Eligible for treatment with pemetrexed-based chemotherapy

3. Creatinine clearance >45ml/min

4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

5. Subject is able and willing to sign the Informed Consent Form

Exclusion Criteria:

1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be assessed by physician)

2. Contraindications for treatment with pemetrexed in line with the summary of product characteristics (SmPC) (except for creatinine clearance <45 ml/min in IMPROVE-I)

1. Hypersensitivity to the active substance or to any of the excipients

2. Pregnancy or lactation

3. Concomitant yellow fever vaccine

3. The presence of clinically relevant pharmacokinetic interactions, according to the current SmPC

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Mesothelioma
• Mesothelioma, Malignant
• Non Small Cell Lung Cancer

Intervention

Drug:
• Pemetrexed
Dosing is either based on BSA or renal function

Locations

Country	Name	City	State
Netherlands	Jeroen Bosch Hospital	's-Hertogenbosch
Netherlands	Antoni van Leeuwenhoek	Amsterdam
Netherlands	Maastricht University Medical centre	Maastricht
Netherlands	Radboud university medical centre	Nijmegen
Netherlands	Erasmus University Medical Centre	Rotterdam

Sponsors (2)

Lead Sponsor	Collaborator
Radboud University Medical Center	ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Exposure (AUC)	mg*h/l	24 hours
Primary	The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing.	The fraction (percentage) of patients with attainment of therapeutic exposure defined as an AUC of 164 mg*h/l ±25%, with pemetrexed dosing based on renal function versus BSA-based dosing.	3 months
Secondary	Population Clearance (Cl)	L/h	3 months
Secondary	Population Intercompartmental Clearance (Q)	L/h	3 months
Secondary	Population Central Volume of Distribution (V1)	L	24 hours
Secondary	Population Peripheral Volume of Distribution (V2)	L	3 months
Secondary	Performance of different renal function algorithms to predict pemetrexed	Significant change in objective function value (OFV) (<3.84 with 1 degree of freedom)	3 months
Secondary	Performance of different renal function algorithms to predict pemetrexed pharmacokinetics (decrease in variability)	Decrease in clearance variablity (%)	3 months
Secondary	Hematologic assessment during dosing based on renal function in patients with a creatinine clearance >45ml/min versus dosing based on BSA.	Complete blood count (no per liter)	5 days
Secondary	The incidence of hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4'	through listing	3 months
Secondary	The incidence of non-hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4	through listing	3 months
Secondary	The incidence of toxicity-related dose reductions, treatment delays and treatment discontinuation	through listing	3 months
Secondary	Quality of life measured with the EORTC QLQ-C30/L13 questionnaire	0-100 scale	3 months
Secondary	In silico evaluation of neutropenic response	Simulation of risk for neutropenic response	1 year
Secondary	Neutropenia related costs	Euros	1 year